Results 71 to 80 of about 692,682 (292)

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice

Journal of Diabetes Research, 2021
Insulin treatment was confirmed to reduce insulin resistance, but the underlying mechanism remains unknown. Caveolin-1 (Cav-1) is a functional protein of the membrane lipid rafts, known as caveolae, and is widely expressed in mammalian adipose tissue ...
Hangya Peng, Panwei Mu, Haicheng Li, Shuo Lin, Chuwen Lin, Keyi Lin, Kunying Liu, Wen Zeng, Longyi Zeng   +8 more
doaj   +1 more source

Insulin‐Dependence and Survival in Pancreatic Neuroendocrine Tumors: Results From the US‐NTSG Group

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction PNETs are rare pancreatic malignancies originating from islet cells and exhibit a strong co‐occurrence with Diabetes Mellitus (DM), associated with worse survival outcomes. However, studies have yet to delineate the impact of insulin dependent (IDDM) and non‐insulin dependent (NIDDM) on poor oncological outcomes. Methods Utilizing
Muhammad Bilal Mirza, Jordan J. Baechle, Paula Marincola Smith, Danish Ali, Mary Dillhoff, George Poultsides, Flavio G. Rocha, Clifford S. Cho, Emily R. Winslow, Ryan C. Fields, Shishir K. Maithel, Kamran Idrees   +11 more
wiley   +1 more source

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]

, 2011
This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +3 more
core  

Insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis

Diabetes, obesity and metabolism, 2020
To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of insulin glargine 100 U/mL and lixisenatide, relative to premix insulin and other insulin options through network meta‐analysis.
P. Home, L. Blonde, S. Kalra, L. Ji, P. Guyot, C. Brulle-Wohlhueter, E. Murray, Roshan P. Shah, T. Sayre, A. Shaunik   +9 more
semanticscholar   +1 more source

Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This post hoc analysis assessed efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec (icodec) versus once‐daily (OD) basal insulin comparators across different baseline glycated haemoglobin (HbA1c), body mass index (BMI) and type 2 diabetes (T2D) duration subgroups using data from five phase 3a trials of icodec in adults with
Alice Y. Y. Cheng, Gayathri Anil, Luis Canani, Siri Vinther, Ni Wang, Chantal Mathieu   +5 more
wiley   +1 more source

Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes [PDF]

, 2010
Introduction: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands.
A. Dornhorst, A. Patel, A. Philis-Tsimikas, A. Rubino, A.B. King, American Diabetes Association., B.J. Borah, D.M. Nathan, Edith M. Heintjes, Fernie J. A. Penning-van Beest, G. Goodall, G. Rutten, G.E.H.M. Rutten, J.B. Brown, J.B. Marks, K. Hermansen, L. Czupryniak, L. Meneghini, L.F. Meneghini, L.F. Meneghini, M. Monami, M. Yenigun, M.J. Calvert, M.P. Herk-Sukel van, O. Pedersen, O.E. Johansen, P. Fontaine, P. Gaede, P. Hollander, P. Raskin, P. Rossetti, R.M.C. Herings, R.M.C. Herings, R.R. Holman, Ron M. C. Herings, S. Mudaliar, S.A. Brunton, S.E. Nelson, S.I. McFarlane, T. Haak, Torsten E. Christensen, Trine L. Thomsen, UK Prospective Diabetes Study, W. Fakhoury   +43 more
core   +1 more source

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study

Diabetes Therapy, 2019
IntroductionThe LIGHTNING study applied conventional and advanced analytic approaches to model, predict, and compare hypoglycemia rates of people with type 2 diabetes (T2DM) on insulin glargine 300 U/ml (Gla-300) with those on first-generation (insulin ...
J. Pettus, R. Roussel, Fang Liz Zhou, Z. Bosnyák, J. Westerbacka, R. Berria, J. Jiménez, B. Eliasson, I. Hramiak, T. Bailey, L. Meneghini   +10 more
semanticscholar   +1 more source

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský, Lenka Thieme, Ivana Laňková, Štěpánka Franková, Alica Veselá, Emil Záhumenský, Tomáš Edelsberger, Marie Löblová, Ondřej Žižka, Miroslav Vytasil, Felipe Lauand, Mireille Bonnemaire, Filip Hrubý, Miloš Mráz, Martin Haluzík   +14 more
wiley   +1 more source

Glargine and degludec: solution behaviour of higher dose synthetic insulins [PDF]

, 2017
Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt ...
A Ortega, A Stradner, B Zinman, C Homko, CM Reno, CN Cramer, D Aizen, D Roith Le, DB Steensgaard, DJ Scott, DR Owens, EJ Dodson, G Bentley, I Zib, J Dam, J Rosenstock, KI Birkeland, M Monami, MC Riddle, MJ Adams, P Kurtzhals, P Schuck, PR Wills, R Solomon Zemler, RB Gillis, S Ang, SE Harding, SE Harding, SJ Jacober, T Heise   +29 more
core   +2 more sources